Table 5.
Effect estimates for the impact of amyloid status on EQ-5D utility trajectory
| Variable | Estimates (SE) | P value |
|---|---|---|
| Clinical stage × time | 0.27 | |
| SCD × time | Reference | |
| MCI × time | 0.003 (0.003) | |
| Dementia × time | 0.007 (0.012) | |
| Clinical stage × amyloid | 0.79 | |
| SCD × amyloid positive | Reference | |
| MCI × amyloid positive | 0 (0.021) | |
| DEM × amyloid positive | 0.031 (0.048) | |
| Time × amyloid positive | − 0.011 (0.004) | < 0.05 |
| Clinical stage × time × amyloid | 0.95 | |
| SCD × time × amyloid positive | Reference | |
| MCI × time × amyloid positive | 0.002 (0.006) | |
| Dementia × time × amyloid positive | 0.003 (0.014) |
Model adjusted for baseline age, sex, education, and BMI
SCD Subjective cognitive decline, MCI Mild cognitive impairment